InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,108.60
(
1.19%
)
US TECH 100
17,293.60
(
1.86%
)
Dow Jones
38,315.93
(
0.60%
)
Brent Oil
88.34
(
0.21%
)
Bitcoin
64,016.22
(
-0.73%
)
Post# of 251616
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

willyw

Send PM Follow Ignore
Followers 14
Posts 730
Boards Moderated 0
Alias Born 12/09/2013

willyw

Re: Bickema post# 182954

Monday, 10/20/2014 11:51:31 AM

Monday, October 20, 2014 11:51:31 AM

Post# of 251616
Some people wonder if Abbvie may now turn it's sight towards ENTA acquisition.

I think the dream of Gilead Harvoni's approval is now older news; many investors then look to the "next" thing.

As we get closer to AASLD I think Abbvie/ENTA HCV presence may get more respect.

Abbvie and ENTA will present on the 2nd gen program, and I believe the 3 day monotherapy will be in the area of 4 log for each compound.

We may get a preview of how they will also work synergistically, not only additively.
~W


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up